Galectin Therapeutics Past Earnings Performance
Past criteria checks 0/6
Galectin Therapeutics's earnings have been declining at an average annual rate of -21.9%, while the Biotechs industry saw earnings growing at 12.3% annually.
Key information
-21.9%
Earnings growth rate
-16.1%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
Galectin rises as FDA approves to begin human trial of combination immunotherapy in head and neck cancer
Oct 12Galectin Therapeutics GAAP EPS of -$0.16
Aug 15Galectin: Ability To Potentially Target Unmet Medical Need
Jul 11Galectin: Pursuing A Subset In The NASH Space
Jul 01Read This Before Buying Galectin Therapeutics, Inc. (NASDAQ:GALT) Shares
Feb 25
Is Galectin Therapeutics (NASDAQ:GALT) In A Good Position To Deliver On Growth Plans?
Jan 21How Much Of Galectin Therapeutics, Inc. (NASDAQ:GALT) Do Insiders Own?
Dec 09Galectin Therapeutics reports Q3 results
Nov 09Revenue & Expenses BreakdownBeta
How Galectin Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -45 | 6 | 32 |
| 30 Sep 23 | 0 | -45 | 6 | 33 |
| 30 Jun 23 | 0 | -40 | 6 | 32 |
| 31 Mar 23 | 0 | -40 | 6 | 32 |
| 31 Dec 22 | 0 | -39 | 7 | 32 |
| 30 Sep 22 | 0 | -35 | 7 | 29 |
| 30 Jun 22 | 0 | -35 | 7 | 29 |
| 31 Mar 22 | 0 | -34 | 7 | 27 |
| 31 Dec 21 | 0 | -31 | 6 | 24 |
| 30 Sep 21 | 0 | -31 | 6 | 24 |
| 30 Jun 21 | 0 | -29 | 6 | 23 |
| 31 Mar 21 | 0 | -26 | 5 | 21 |
| 31 Dec 20 | 0 | -24 | 5 | 18 |
| 30 Sep 20 | 0 | -21 | 5 | 15 |
| 30 Jun 20 | 0 | -18 | 6 | 12 |
| 31 Mar 20 | 0 | -15 | 6 | 9 |
| 31 Dec 19 | 0 | -20 | 6 | 7 |
| 30 Sep 19 | 0 | -18 | 6 | 5 |
| 30 Jun 19 | 0 | -19 | 6 | 5 |
| 31 Mar 19 | 0 | -20 | 7 | 5 |
| 31 Dec 18 | 0 | -15 | 7 | 6 |
| 30 Sep 18 | 0 | -14 | 7 | 6 |
| 30 Jun 18 | 0 | -16 | 6 | 8 |
| 31 Mar 18 | 0 | -17 | 5 | 10 |
| 31 Dec 17 | 0 | -17 | 5 | 12 |
| 30 Sep 17 | 0 | -20 | 5 | 14 |
| 30 Jun 17 | 0 | -20 | 6 | 14 |
| 31 Mar 17 | 0 | -21 | 6 | 15 |
| 31 Dec 16 | 0 | -22 | 6 | 15 |
| 30 Sep 16 | 0 | -22 | 6 | 15 |
| 30 Jun 16 | 0 | -24 | 6 | 16 |
| 31 Mar 16 | 0 | -23 | 7 | 14 |
| 31 Dec 15 | 0 | -21 | 7 | 13 |
| 30 Sep 15 | 0 | -20 | 7 | 12 |
| 30 Jun 15 | 0 | -18 | 7 | 10 |
| 31 Mar 15 | 0 | -17 | 6 | 9 |
| 31 Dec 14 | 0 | -17 | 7 | 8 |
| 30 Sep 14 | 0 | -16 | 6 | 8 |
| 30 Jun 14 | 0 | -16 | 7 | 7 |
| 31 Mar 14 | 0 | -24 | 6 | 7 |
| 31 Dec 13 | 0 | -22 | 5 | 6 |
| 30 Sep 13 | 0 | -22 | 6 | 5 |
Quality Earnings: GALT is currently unprofitable.
Growing Profit Margin: GALT is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: GALT is unprofitable, and losses have increased over the past 5 years at a rate of 21.9% per year.
Accelerating Growth: Unable to compare GALT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GALT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: GALT's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.